A clinical perspective on muscle specific kinase antibody positive myasthenia gravis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39703505/
The discovery of autoantibodies directed against muscle-specific kinase (MuSK) in "seronegative" myasthenia gravis (MG) patients marked a milestone in MG research. In healthy muscle, MuSK regulates a phosphorylation pathway, which...
MuSK-MG is an autoimmune disorder characterized by IgG4 antibodies targeting muscle-specific kinase, impairing acetylcholine receptor clustering. Rituximab is effective in treatment, improving clinical outcomes compared to corticosteroids and immunosuppressants.
Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39872531/
Though MG typically precedes NMOSD and thymectomy is frequently performed, it is not a prerequisite for NMOSD development but may represent a potential risk factor. MG generally follows a benign...
This study explores the clinical features and treatment strategies for concurrent neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), highlighting the efficacy of inebilizumab in disease control and relapse prevention.
Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38881805/
Overall, in light of the known pathogenesis and association of the thymus with MG, thymectomy remains an extremely effective approach for long-term management and improved clinical outcomes.
This review explores thymectomy's role in managing Myasthenia Gravis (MG), highlighting its effectiveness in improving clinical outcomes, addressing thymic pathologies, and examining factors influencing patient outcomes and complications.
Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38398450/
Myasthenia gravis (MG) is a rare autoimmune disease. Transient neonatal myasthenia gravis (TNMG) is caused by pathogenic maternal autoantibodies that cross the placenta and disrupt signaling at the neuromuscular junction....
Transient neonatal myasthenia gravis (TNMG) is a rare, IgG-mediated autoimmune disease affecting neonates of mothers with myasthenia gravis, often self-limiting, but can cause severe symptoms or permanent complications.
Association Between the Immune Checkpoint Inhibitor Durvalumab and Myasthenia Gravis: A Comprehensive Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39364500/
Immune checkpoint inhibitors (ICIs), including Imfinzi (durvalumab), have revolutionized cancer treatment by stimulating the body's immune system to target cancerous cells. Although pharmaceuticals offer therapeutic benefits, several drugs have been...
Durvalumab-induced myasthenia gravis (MG) is a rare but serious immune-related adverse event. Monitoring, early identification, and proper management are crucial, requiring further research to optimize patient outcomes and treatment protocols.